Mucocutaneous Lymph Node Syndrome
"Mucocutaneous Lymph Node Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.
Below are MeSH descriptors whose meaning is more general than "Mucocutaneous Lymph Node Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Mucocutaneous Lymph Node Syndrome".
This graph shows the total number of publications written about "Mucocutaneous Lymph Node Syndrome" by people in this website by year, and whether "Mucocutaneous Lymph Node Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Mucocutaneous Lymph Node Syndrome" by people in Profiles.
Cytokine cascade in Kawasaki disease versus Kawasaki-like syndrome. Physiol Res. 2022 03 25; 71(1):17-27.
Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol. 2021 12; 17(12):731-748.
Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis. JCI Insight. 2021 09 22; 6(18).
NLRP3 Inflammasome Mediates Immune-Stromal Interactions in Vasculitis. Circ Res. 2021 10 15; 129(9):e183-e200.
Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. Nat Commun. 2021 08 11; 12(1):4854.
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020 07 23; 383(4):334-346.
Kawasaki Disease: Beyond IVIG and Aspirin. Pediatr Ann. 2019 Oct 01; 48(10):e400-e405.
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemp Clin Trials. 2019 04; 79:98-103.
Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment. Hum Mol Genet. 2018 08 01; 27(15):2671-2677.
The transcriptional profile of coronary arteritis in Kawasaki disease. BMC Genomics. 2015 Dec 18; 16:1076.